Champions Oncology Inc.

7.75+0.1800+2.38%Vol 9.44K1Y Perf -21.72%
Jun 24th, 2022 16:00 DELAYED
BID5.87 ASK9.44
Open7.57 Previous Close7.57
Pre-Market- After-Market-
 - -  - -%
Target Price
13.50 
Analyst Rating
Strong Buy 1.00
Potential %
74.19 
Finscreener Ranking
★+     44.03
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
     30.68
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★+     47.86
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
21.17 
Earnings Rating
Strong Sell
Market Cap104.80M 
Earnings Date
28th Jul 2022
Alpha0.03 Standard Deviation0.20
Beta1.03 

Today's Price Range

7.577.75

52W Range

6.8111.25

5 Year PE Ratio Range

-37.101.04K

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
2.38%
1 Month
5.01%
3 Months
-8.82%
6 Months
-3.61%
1 Year
-21.72%
3 Years
-3.97%
5 Years
191.35%
10 Years
57.52%

TickerPriceChg.Chg.%
CSBR7.750.18002.38
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
1.10
1.20
0.48
1.04
-
Leverage Ratio 3.70
ProfitabilityValueIndustryS&P 500US Markets
48.60
0.60
3.50
-2.00
2.46
RevenueValueIndustryS&P 500US Markets
36.23M
2.68
12.01
20.97
Earnings HistoryEstimateReportedSurprise %
Q03 20220.030.0566.67
Q02 20220.000.02-
Q01 20220.01-0.01-200.00
Q04 20210.01-0.04-500.00
Q03 20210.010.05400.00
Q02 20210.010.00-100.00
Q01 20210.020.01-50.00
Q04 20200.01-0.17-1 800.00
Earnings Per EndEstimateRevision %Trend
4/2022 QR0.02-33.33Negative
4/2022 QR0.03-25.00Negative
4/2022 FY0.0814.29Positive
4/2023 FY0.250.00-
Next Report Date28th Jul 2022
Estimated EPS Next Report0.02
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume9.44K
Shares Outstanding13.52K
Shares Float6.94M
Trades Count118
Dollar Volume72.67K
Avg. Volume2.54K
Avg. Weekly Volume1.68K
Avg. Monthly Volume2.06K
Avg. Quarterly Volume3.88K

Champions Oncology Inc. (NASDAQ: CSBR) stock closed at 7.75 per share at the end of the most recent trading day (a 2.38% change compared to the prior day closing price) with a volume of 9.44K shares and market capitalization of 104.80M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 143 people. Champions Oncology Inc. CEO is Ronnie Morris.

The one-year performance of Champions Oncology Inc. stock is -21.72%, while year-to-date (YTD) performance is -7.3%. CSBR stock has a five-year performance of 191.35%. Its 52-week range is between 6.81 and 11.25, which gives CSBR stock a 52-week price range ratio of 21.17%

Champions Oncology Inc. currently has a PE ratio of 757.00, a price-to-book (PB) ratio of 11.08, a price-to-sale (PS) ratio of 2.83, a price to cashflow ratio of 29.10, a PEG ratio of 2.32, a ROA of 0.77%, a ROC of 1.32% and a ROE of 2.65%. The company’s profit margin is 2.46%, its EBITDA margin is 3.50%, and its revenue ttm is $36.23 Million , which makes it $2.68 revenue per share.

Of the last four earnings reports from Champions Oncology Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.02 for the next earnings report. Champions Oncology Inc.’s next earnings report date is 28th Jul 2022.

The consensus rating of Wall Street analysts for Champions Oncology Inc. is Strong Buy (1), with a target price of $13.5, which is +74.19% compared to the current price. The earnings rating for Champions Oncology Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Champions Oncology Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Champions Oncology Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 9.77, ATR14 : 0.21, CCI20 : 130.19, Chaikin Money Flow : 0.32, MACD : 0.04, Money Flow Index : 77.60, ROC : 5.01, RSI : 56.61, STOCH (14,3) : 78.26, STOCH RSI : 1.00, UO : 62.50, Williams %R : -21.74), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Champions Oncology Inc. in the last 12-months were: David Sidransky (Option Excercise at a value of $26 501), Scott R. Tobin (Option Excercise at a value of $15 900)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (100.00 %)
1 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Champions Oncology Inc.

Champions Oncology Inc is a US-based company which is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies.

CEO: Ronnie Morris

Telephone: +1 201 808-8400

Address: One University Plaza, Hackensack 07601, NJ, US

Number of employees: 143

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

100%0%

Bearish Bullish

47%53%

Bearish Bullish

62%38%

News

Stocktwits